Tag Archives: Against

Clovis investors lose faith as Rubraca struggles against Big Pharma’s marketing giants

It’s no secret that Clovis Oncology is up against some serious marketing muscle in the PARP inhibitor arena. And investors are doubting the company’s ability to hang in there. Shareholders headed for the exits Thursday after Clovis reported that Rubraca sales tallied just $ 33 million in the second quarter, coming in $ 2 million… Read More »

How to improve defenses against health data security threats

Healthcare institutions are trusted with our most valuable information. Within their networks they store highly sensitive data such as medical records, treatment plans, financial records, contact information and more. This data is essential for healthcare providers to effectively communicate with patients and provide the best care possible. However, having this information is also what makes… Read More »